Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review)
| Autor: | Stephanie Iraiz Nuñez Olvera, Euclides Jordan‑Alejandre, Isaac Compean Martínez, Maria Zenaida Saavedra Leos, César López‑Camarillo, Macrina Beatriz Silva Cázares |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Small interfering RNA Antineoplastic Agents Breast Neoplasms Injections Intralesional Metastasis 03 medical and health sciences Mice 0302 clinical medicine Breast cancer Cell Line Tumor microRNA medicine Animals Humans Breast RNA Small Interfering Oncogene business.industry Cancer General Medicine Cell cycle medicine.disease Non-coding RNA Lipids Xenograft Model Antitumor Assays Gene Expression Regulation Neoplastic Disease Models Animal MicroRNAs 030104 developmental biology Oncology 030220 oncology & carcinogenesis Liposomes Cancer research Nanoparticles Female business |
| Zdroj: | Oncology reports. 44(6) |
| ISSN: | 1791-2431 |
| Popis: | Breast cancer is the most common type of cancer with the highest morbidity and mortality rates in women worldwide. Recent efforts to improve the current antitumor therapies have led to the development of novel treatment approaches based on the delivery of therapeutic non‑coding RNAs (ncRNAs) using nanotechnology. Treatment methods using lipid‑based nanoparticles (LBNPs) have greatly improved the delivery efficiency of ncRNAs into tumor cells and tissues. This type of delivery approach has provided significant advantages, such as reduced therapeutic doses, lower cytotoxicity to normal cells and the ability to reverse resistance to chemotherapy. LBNPs have demonstrated the ability to deliver therapeutic ncRNAs, more specifically microRNAs (miRNAs) and small interfering RNAs (siRNAs); this has been reported modulate the expression levels of oncogenes and tumor suppressor genes involved in several biological processes, including cell growth and proliferation, cell death, invasion and metastasis, thus impairing the malignant behavior of tumors. Therefore, ncRNA‑based therapies combined with the LBNP delivery strategy, namely nanomiRNAs, may represent a promising antitumor strategy guaranteeing superior biocompatibility, higher biodegradability, lower immunogenicity and decreased toxicity to normal cells compared with other therapeutic approaches. The present review summarized the current knowledge of the application of LBNPs for delivering miRNAs and siRNAs in breast cancer cells and mouse models, in addition to discussing their promising antitumor effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|